U. Y. Arslan Et Al. , "Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients," JOURNAL OF BUON , vol.18, no.3, pp.585-593, 2013
Arslan, U. Y. Et Al. 2013. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. JOURNAL OF BUON , vol.18, no.3 , 585-593.
Arslan, U. Y., Turker, I., Aksoy, S., Oksuzoglu, B., Helvaci, K., Ozdemir, N. Y., ... Uyeturk, U.(2013). Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. JOURNAL OF BUON , vol.18, no.3, 585-593.
Arslan, U. Et Al. "Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients," JOURNAL OF BUON , vol.18, no.3, 585-593, 2013
Arslan, U. Y. Et Al. "Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients." JOURNAL OF BUON , vol.18, no.3, pp.585-593, 2013
Arslan, U. Y. Et Al. (2013) . "Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients." JOURNAL OF BUON , vol.18, no.3, pp.585-593.
@article{article, author={U. Y. Arslan Et Al. }, title={Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients}, journal={JOURNAL OF BUON}, year=2013, pages={585-593} }